首页> 美国卫生研究院文献>Haematologica >Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

【2h】

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

机译：大剂量伊马替尼与第二代酪氨酸激酶抑制剂的一线治疗对慢性期慢性粒细胞白血病患者的倾向评分分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Haematologica
作者
Koji Sasaki; Hagop Kantarjian; Elias Jabbour; Farhad Ravandi; Koichi Takahashi; Marina Konopleva; Gautam Borthakur; Guillermo Garcia-Manero; William Wierda; Naval Daver; Preetesh Jain; Toshihisa Satta; Sherry Pierce; May Beth Rios; Jorge E. Cortes;
展开▼
作者单位

展开▼
年(卷),期 2016(101),8
年度 2016
页码 e324–e327
总页数 4
原文格式 PDF
正文语种
中图分类血液学检验;
关键词
chronic myeloid leukemia high-dose imatinib nilotinib dasatinib;

机译：慢性粒细胞白血病;大剂量伊马替尼;尼洛替尼;达沙替尼;

相似文献

外文文献
中文文献
专利

1. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis [J] . Koji Sasaki, Hagop Kantarjian, Elias Jabbour, Haematologica . 2016,第8期

机译：大剂量伊马替尼与第二代酪氨酸激酶抑制剂的一线治疗对慢性期慢性粒细胞白血病患者的倾向评分分析
2. Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70. [J] . Doggrell SA, Christensen AM Expert opinion on pharmacotherapy . 2011,第1期

机译：是否有比伊马替尼更好的Bcr-Abl激酶抑制剂用于慢性粒细胞白血病？ Saglio G，Kim D-W，Issaragrisil S等的评估。尼洛替尼与伊马替尼治疗新诊断的慢性粒细胞白血病。 N Engl J Med 2010; 362：2251-9，and Kantarjian H，Shah NP，Hochhaus A等。达沙替尼与伊马替尼治疗新近诊断的慢性期慢性粒细胞白血病。 N Engl J Med 2010; 362：2260-70。
3. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials [J] . Yun Seongseok, Vincelette Nicole D., Segar Jennifer M., Clinical lymphoma, myeloma & leukemia . 2016,第6期

机译：新型酪氨酸激酶抑制剂与伊马替尼在不同风险组的一线治疗慢性粒细胞性白血病一线治疗中的比较有效性：八项随机试验的系统评价和荟萃分析
4. Combination effects of repetitive pulsed magnetic stimulation and tyrosine kinase inhibitor imatinib for chronic myeloid leukemia cell line TCC-S [C] . S. Yamaguchi, M. Sekino, Y. Sato, Intermag Conference . 2006

机译：重复脉冲磁刺激和酪氨酸激酶抑制剂慢性髓性白血病细胞系TCC-S的组合效应
5. Influences on physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia patients. [D] . Iyer, Shrividya Sethuraman. 2003

机译：对慢性期慢性粒细胞白血病患者甲磺酸伊马替尼的医师推荐的影响。
6. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10 of BCR-ABL/ABL ratio at 3 months [O] . Luis-Felipe Casado, José-Valentín García-Gutiérrez, Isabel Massagué, 2015

机译：改用第二代酪氨酸激酶抑制剂可改善一线伊马替尼治疗的慢性粒细胞白血病患者的反应和预后在3个月时其BCR-ABL / ABL比率超过10％
7. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population [O] . Budi Suprapti, Mareta Rindang Andarsari, Pharmasinta Putri Hapsari, 2020

机译：酪氨酸激酶抑制剂（伊马替尼和Nilotinib）的槽水平与印度尼西亚慢性相慢性骨髓白血病（CML）群体的BCR-ABL比的关系

Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia – a propensity score analysis

著录项

相似文献

相关主题

期刊订阅